KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Recursion Pharmaceuticals (RXRX) Receivables - Other (2021 - 2025)

Historic Receivables - Other for Recursion Pharmaceuticals (RXRX) over the last 5 years, with Q3 2025 value amounting to $5.6 million.

  • Recursion Pharmaceuticals' Receivables - Other rose 14833.7% to $5.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.6 million, marking a year-over-year increase of 14833.7%. This contributed to the annual value of $7.9 million for FY2024, which is 15533.29% up from last year.
  • As of Q3 2025, Recursion Pharmaceuticals' Receivables - Other stood at $5.6 million, which was up 14833.7% from $21.6 million recorded in Q2 2025.
  • In the past 5 years, Recursion Pharmaceuticals' Receivables - Other registered a high of $49.2 million during Q4 2024, and its lowest value of $2.1 million during Q1 2023.
  • Its 5-year average for Receivables - Other is $9.1 million, with a median of $5.6 million in 2025.
  • As far as peak fluctuations go, Recursion Pharmaceuticals' Receivables - Other plummeted by 8189.74% in 2023, and later skyrocketed by 148907.56% in 2024.
  • Quarter analysis of 5 years shows Recursion Pharmaceuticals' Receivables - Other stood at $9.1 million in 2021, then plummeted by 69.6% to $2.8 million in 2022, then increased by 12.39% to $3.1 million in 2023, then soared by 1489.08% to $49.2 million in 2024, then tumbled by 88.61% to $5.6 million in 2025.
  • Its last three reported values are $5.6 million in Q3 2025, $21.6 million for Q2 2025, and $6.2 million during Q1 2025.